GHK-Cu Field Guide
Chapter 04 / Dosage & Chemistry

GHK-Cu Dosage in Published Research: Routes, Concentrations, and Copper Chemistry

What the peer-reviewed record documents — topical concentrations, animal model doses, reconstitution science, and the open questions in human pharmacokinetics.

Read the mechanism See references
Flat illustration comparing a blue-violet intact copper-peptide vial with a green check and an oxidized green-brown vial with a magenta cross

GHK-Cu Dosage in Published Research

Research Context Only

GHK-Cu is a research peptide compound without an FDA-approved drug indication for any route of administration. No validated human systemic dosing protocol exists in the peer-reviewed literature. What follows is a summary of the doses used in published studies — not a dosing recommendation.

Human topical studies. Topical GHK-Cu concentrations in published human cosmetic and dermatological studies range from 0.1% to 3%. The Badenhorst (2016) nanocarrier wrinkle study did not fully disclose concentration; the ALAVAX hair trial used 50–100 mg/mL of the GHK peptide complex.[6][18]

Human clinical pharmacokinetics. No formal Phase I human pharmacokinetic study for systemic GHK-Cu has been registered on ClinicalTrials.gov or published in peer-reviewed literature. The plasma half-life after intravenous administration is estimated at approximately 0.5–1 hour based on rapid peptidase degradation kinetics in plasma — an estimate from analogy, not direct measurement.

Animal intraperitoneal studies. The lung protection studies used GHK-Cu at 0.2, 2, 20 μg/g/day IP in C57BL/6J mice.[9] The pulmonary fibrosis studies used 2.6, 26, 260 μg/mL/day IP on alternating days.[8] The skeletal muscle studies used 0.2 and 2 mg/kg IP.[10]

Animal intranasal studies. The aging-mouse cognitive study used GHK-Cu at 15 mg/kg/day intranasal for 8 weeks in 20-month-old mice.[15]

In-vitro cell studies. Fibroblast collagen stimulation was measured from 10⁻¹² to 10⁻⁹ M in cell culture medium.[1]

GHK-Cu Dosing Ranges in Animal and Human Studies

Species / Model Route Dose Range Study Focus
Human fibroblasts (in vitro) Cell culture 10⁻¹² – 10⁻⁹ M Collagen synthesis [1]
Human skin (ex vivo) Topical 0.1–3% in formulation Penetration, collagen [13][18]
Human (RCT, topical) Topical 50–100 mg/mL (ALAVAX) Hair growth [6]
Mouse C57BL/6J (IP) Intraperitoneal 0.2, 2, 20 μg/g/day Lung protection [9]
Mouse C57BL/6 (IP) Intraperitoneal 2.6, 26, 260 μg/mL/day Pulmonary fibrosis [8]
Mouse (IP) Intraperitoneal 0.2, 2 mg/kg Skeletal muscle [10]
Mouse aging (intranasal) Intranasal 15 mg/kg/day × 8 wk Cognitive aging [15]
Mouse (topical microemulsion) Topical CaT-ME formulation Hair follicle [7]

The dose ranges are not directly comparable across routes, species, and tissue targets. No dose-conversion factor from animal IP doses to human topical concentrations is established in the literature.

GHK-Cu Half-Life and Pharmacokinetics

Formal published pharmacokinetic data for GHK-Cu after IV or subcutaneous administration in humans does not exist. The following is based on available indirect evidence.

The parent tripeptide GHK is subject to rapid hydrolysis by plasma peptidases — proline endopeptidase, aminopeptidases, and non-specific endopeptidases all cleave small tripeptides in plasma within minutes to hours. Based on this peptide degradation kinetics, the plasma half-life after IV administration is estimated at approximately 0.5–1 hour.

Copper chelation by GHK alters the peptide's stability relative to the free form: the coordination bond to Cu(II) via the histidine imidazole nitrogen makes the peptide more resistant to peptidase activity at physiological pH. Whether this extends the functional half-life significantly in plasma or tissue is not established in the published record.

Topical pharmacokinetics are better characterized. In-vitro human skin permeation data shows the stratum corneum accumulating 438-fold over baseline copper levels and the epidermis 165-fold over 48 hours, with approximately 2% total penetration through to the dermis.[13] A tissue depot forms in the stratum corneum that may provide a sustained slow-release effect over hours to days.

Why GHK-Cu Solution Appears Blue: The Chemistry Explained

Good to Know

Reconstituted GHK-Cu solution is blue-violet in color. This is expected and indicates the compound is intact. The color arises from the Cu(II) d-orbital electronic absorption — a characteristic absorption band in the 500–600 nm range that is present whenever copper(II) is in the stable chelation geometry of the GHK-Cu complex.[22]

A color shift after reconstitution indicates a problem:

Green or brown. Indicates Cu(II) oxidation to Cu(III) or precipitation of copper as hydroxide or oxide. The peptide-copper coordination bond has broken and the compound has degraded — the active chelated form studied in the literature is no longer present.[22]

Yellow or colorless. Could indicate very high dilution, incorrect reconstitution (wrong solvent, wrong pH), or loss of copper during storage. Not the expected appearance of correctly reconstituted GHK-Cu.

Practical stability notes from the research literature: optimal storage of lyophilized GHK-Cu is at -20°C, protected from moisture and light — stable for 12–24 months. Reconstituted solution should be stored at 4°C and used within 2–4 weeks to minimize oxidation.[22]

Reconstituted GHK-Cu Color Changes: Oxidation and Stability

Brown or green coloration after reconstitution indicates copper oxidation from Cu(II) to Cu(III) or precipitation. This means the copper-peptide coordination bond has broken and the compound is no longer the active chelated form documented in the research literature.[22]

Vitamin C Incompatibility

Ascorbic acid (Vitamin C) at pH 2.5–3.5 will reduce Cu(II) to Cu(I) and destroy both the copper peptide and the ascorbic acid simultaneously.[22] Research formulation protocols use separate application windows — copper peptide and Vitamin C are not combined in the same vehicle.

The oxidation pathway: Cu(II) in the GHK-Cu complex is reduced to Cu(I) by strong reducing agents (ascorbic acid at pH <3.5 is the most common cause) or to Cu(III) by oxidative conditions. Both oxidation states break the specific coordination geometry responsible for the compound's biological activity.

Reconstituted GHK-Cu storage from the research literature: 4°C storage, use within 2–4 weeks after reconstitution to minimize oxidation.[22] Lyophilized peptide stored at -20°C is stable for 12–24 months when protected from moisture and light.